These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 31190948)

  • 1. Why targeting the microbiome is not so successful: can randomness overcome the adaptation that occurs following gut manipulation?
    Ilan Y
    Clin Exp Gastroenterol; 2019; 12():209-217. PubMed ID: 31190948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in microbial ecology after fecal microbiota transplantation for recurrent C. difficile infection affected by underlying inflammatory bowel disease.
    Khanna S; Vazquez-Baeza Y; González A; Weiss S; Schmidt B; Muñiz-Pedrogo DA; Rainey JF; Kammer P; Nelson H; Sadowsky M; Khoruts A; Farrugia SL; Knight R; Pardi DS; Kashyap PC
    Microbiome; 2017 May; 5(1):55. PubMed ID: 28506317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Possibilities of therapeutic manipulation of the gut microbiota].
    Drastich P; Bajer L; Kverka M
    Vnitr Lek; 2018; 64(6):665-671. PubMed ID: 30223665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gut Microbiota and Chronic Constipation: A Review and Update.
    Ohkusa T; Koido S; Nishikawa Y; Sato N
    Front Med (Lausanne); 2019; 6():19. PubMed ID: 30809523
    [No Abstract]   [Full Text] [Related]  

  • 5. Fecal Microbiota Transplantation for the Critically Ill Patient.
    Limketkai BN; Hendler S; Ting PS; Parian AM
    Nutr Clin Pract; 2019 Feb; 34(1):73-79. PubMed ID: 30561131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics.
    Cho MS; Kim SY; Suk KT; Kim BY
    J Microbiol; 2018 Dec; 56(12):855-867. PubMed ID: 30377993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of the microbiome for human health: from basic science to clinical applications.
    Mohajeri MH; Brummer RJM; Rastall RA; Weersma RK; Harmsen HJM; Faas M; Eggersdorfer M
    Eur J Nutr; 2018 May; 57(Suppl 1):1-14. PubMed ID: 29748817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic interventions for gut dysbiosis and related disorders in the elderly: antibiotics, probiotics or faecal microbiota transplantation?
    Vemuri RC; Gundamaraju R; Shinde T; Eri R
    Benef Microbes; 2017 Apr; 8(2):179-192. PubMed ID: 28008784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Efficacy and Microbiome Changes Following Fecal Microbiota Transplantation in Children With Recurrent Clostridium Difficile Infection.
    Li X; Gao X; Hu H; Xiao Y; Li D; Yu G; Yu D; Zhang T; Wang Y
    Front Microbiol; 2018; 9():2622. PubMed ID: 30450088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gut microbiota role in irritable bowel syndrome: New therapeutic strategies.
    Distrutti E; Monaldi L; Ricci P; Fiorucci S
    World J Gastroenterol; 2016 Feb; 22(7):2219-41. PubMed ID: 26900286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Super-Donor Phenomenon in Fecal Microbiota Transplantation.
    Wilson BC; Vatanen T; Cutfield WS; O'Sullivan JM
    Front Cell Infect Microbiol; 2019; 9():2. PubMed ID: 30719428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in Composition of the Gut Bacterial Microbiome after Fecal Microbiota Transplantation for Recurrent
    Flannigan KL; Rajbar T; Moffat A; McKenzie LS; Dicke F; Rioux K; Workentine ML; Louie TJ; Hirota SA; Greenway SC
    Front Cardiovasc Med; 2017; 4():17. PubMed ID: 28421185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Gut Microbiome as a Target for IBD Treatment: Are We There Yet?
    Knox NC; Forbes JD; Van Domselaar G; Bernstein CN
    Curr Treat Options Gastroenterol; 2019 Mar; 17(1):115-126. PubMed ID: 30661163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging role of fecal microbiota therapy in the treatment of gastrointestinal and extra-gastrointestinal diseases.
    Konturek PC; Haziri D; Brzozowski T; Hess T; Heyman S; Kwiecien S; Konturek SJ; Koziel J
    J Physiol Pharmacol; 2015 Aug; 66(4):483-91. PubMed ID: 26348073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulating Composition and Metabolic Activity of the Gut Microbiota in IBD Patients.
    Matijašić M; Meštrović T; Perić M; Čipčić Paljetak H; Panek M; Vranešić Bender D; Ljubas Kelečić D; Krznarić Ž; Verbanac D
    Int J Mol Sci; 2016 Apr; 17(4):. PubMed ID: 27104515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can inflammatory bowel disease be permanently treated with short-term interventions on the microbiome?
    Berg D; Clemente JC; Colombel JF
    Expert Rev Gastroenterol Hepatol; 2015 Jun; 9(6):781-95. PubMed ID: 25665875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Fecal microbiota transplantation].
    Lübbert C; Salzberger B; Mössner J
    Internist (Berl); 2017 May; 58(5):456-468. PubMed ID: 28235986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Liver diseases: The pathogenetic role of the gut microbiome and the potential of treatment for its modulation].
    Aitbaev KA; Murkamilov IT; Fomin VV
    Ter Arkh; 2017; 89(8):120-128. PubMed ID: 28914862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
    Suk KT; Kim DJ
    Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The involvement of gut microbiota in inflammatory bowel disease pathogenesis: potential for therapy.
    Cammarota G; Ianiro G; Cianci R; Bibbò S; Gasbarrini A; Currò D
    Pharmacol Ther; 2015 May; 149():191-212. PubMed ID: 25561343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.